Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus acidophilus KBL409
- Development stage
- Preclinical
- Lead developer
- KoBioLabs
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus acidophilus KBL409 is a probiotic bacterial strain isolated from the feces of a healthy Korean male donor, developed by KoBioLabs and its joint venture weBiom. It is being investigated for its therapeutic and protective effects in chronic kidney disease (CKD) and atopic dermatitis. In preclinical models of CKD, KBL409 administration reduces kidney fibrosis, decreases serum levels of uremic toxins (such as indoxyl sulfate and p-cresyl sulfate), and improves mitochondrial function by restoring PGC-1α and AMPK expression. In a multi-center, randomized, double-blind, placebo-controlled human study, KBL409 supplementation significantly reduced serum indoxyl sulfate concentrations by modulating the gut microbiota. Additionally, KBL409 has demonstrated anti-inflammatory and immunomodulatory properties in mouse models of atopic dermatitis, reducing dermatitis scores and downregulating Th1, Th2, and Th17 cytokines.
- Other names
- L. acidophilus KBL409Lactobacillus acidophilus KBL409 (KCTC 13518BP)
Beyond the preview
Go deeper on Lactobacillus acidophilus KBL409.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus acidophilus KBL409.